|
Oct 7
|
NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan
|
|
Oct 7
|
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
|
|
Sep 26
|
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
|
|
Sep 25
|
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
|
|
Sep 23
|
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
|
|
Jul 18
|
OPKO Health Announces $100 Million Share Repurchase Program
|
|
Jul 17
|
OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments
|
|
Jun 6
|
Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?
|
|
May 9
|
OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y
|
|
May 8
|
OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Q1 2024 OPKO Health Inc Earnings Call
|
|
May 8
|
OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves Amid ...
|
|
May 8
|
Opko Health (OPK) Q1 2024 Earnings Call Transcript
|
|
May 8
|
OPKO Health (OPK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
May 7
|
OPKO Health Inc (OPK) Q1 2024 Earnings: Misses Revenue and Earnings Estimates
|
|
May 7
|
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 7
|
OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
|
|
May 3
|
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
|
|
Apr 1
|
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
|
|
Apr 1
|
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
|